Antibody Discovery Industry Leaders Speak at Carterra’s September 18, 2018 Seminar
Array SPR has facilitated a paradigm shift in antibody screening, enabling higher information content assays to be conducted earlier in the research pipeline to streamline lead selection. This essentially combines screening and detailed characterization in the same step.
Expert View Article in Drug Target Review
Explore the full kinetic and epitope diversity of large antibody libraries with high throughput Array SPR (Surface Plasmon Resonance).
DDW Article on Analytical Biophysical Tools To Accelerate Discovery of Therapeutic Antibodies
The demand for higher throughput analytics is needed to support the paradigm shift that is emerging in the industry towards a deeper appreciation of the epitope diversity offered within an antibody library by applying higher resolution and higher throughput methods for epitope characterization at the earliest stages of research.
Carterra CEO, Josh Eckman, Recognized as a Rising Star by the David Eccles School of Business
Carterra® Inc., a provider of innovative drug discovery technologies, announced that its CEO, Josh Eckman, has been honored as a Rising Star by The University of Utah David Eccles School of Business during its 2018 Hall of Fame induction ceremony.
LakePharma Expands Service Capability with Purchase of Carterra High Throughput Antibody Characterization LSA™ Instrumentation
First Contract Development & Manufacturing Organization to Install Carterra’s Next Generation Label-Free Biosensor to Support Antibody Discovery Services Business
Institute for Protein Innovation Buys Carterra Next-Generation Antibody Characterization LSA™ Instrumentation
First Research Institution to Purchase Carterra’s High-Throughput Label-Free Biosensor to Support its Novel Antibody Discovery
Carterra Announces Multiple Sales of its New LSA™ Array SPR Instrument for Comprehensive Monoclonal Antibody Characterization
First LSA instrument sales are to a broad range of initial customers, including large pharmaceutical, biotech, CRO and academic institutions.
Carterra Inc. Raises $10M from Telegraph Hill Partners to Develop and Launch Next-Generation Antibody Characterization Platform
Additional Resources Will Drive Commercialization of Novel High-Throughput Label-Free Biosensor for Streamlined Antibody Characterization.
GEN Tutorial on High Throughput Antibody Characterization
Learn about epitope binning for next-generation biotherapeutic discovery.
Wasatch Microfluidics Announces Name Change to Carterra Inc. and New High Throughput SPR Instrument
New corporate name and system reflect the evolution of the Company into a premier provider of biotherapeutic characterization tools.